The pharmaceutical industry faces a perfect storm, with unsustainable growth in healthcare costs, increasing costs of drug discovery, and the shift to a value-based payment model.
The benefits of adherent patients are no secret: better outcomes, a more stable treatment pathway and of course better revenues for pharma are all possible.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh